The proposed acquisition would combine the two largest providers of outsourced hydrophilic coatings, Surmodics and Biocoat, which is majority owned by GTCR, giving the merged company control of over 50% of the market, according to a March 6 news release from the agency.
The coatings play a vital role in medical devices such as catheters and guidewires.
The FTC warned that eliminating competition between Surmodics and Biocoat would lead to high prices, reduced innovation and lower-quality products, ultimately harming medical devices and patients.
Becker’s reached out to GTCR BC Holdings and Surmodics for comment and will update this story if more information becomes available.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.